CytoDyn

CYDY

Biotechnology · Healthcare

Price

$0.21

-0.01 (-3.23%)

Market Cap

$287.6M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+111.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 587.6M (2021) → 1.24B (2025)

CytoDyn is a small biotech company focused on developing a single experimental drug called leronlimab, which is designed to block a protein that certain viruses and cancer cells use to spread through the body. The company has tested leronlimab in HIV, cancer, and other diseases, and its potential customers would be patients and healthcare providers if the drug ever reaches approval. CytoDyn does not yet have an approved product on the market.

The company generates almost no revenue today and funds its operations primarily through selling new shares of stock, which dilutes existing shareholders over time. It operates mainly in the United States and is considered a clinical-stage company, meaning it spends money on research without consistent product sales. The biggest risk CytoDyn faces is whether leronlimab can successfully pass clinical trials and receive FDA approval, without which the company has no clear path to becoming a sustainable business.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+4.8% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$17M/ year

↑ Rising (+134% vs prior year)

R&D investment increasing — building for the future

Insider Activity

0.3%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~9 months

$16M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

CytoDyn has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-11932.0%

Shrinking sales (-11932.0% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial